Liquidia (NASDAQ:LQDA – Get Free Report) and TherapeuticsMD (NASDAQ:TXMD – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.
Profitability
This table compares Liquidia and TherapeuticsMD’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Liquidia | 30.74% | 149.65% | 36.30% |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
Institutional and Insider Ownership
64.5% of Liquidia shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 25.6% of Liquidia shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Liquidia | $158.32 million | 38.80 | -$68.92 million | $1.37 | 50.09 |
| TherapeuticsMD | $3.02 million | 8.58 | -$570,000.00 | $0.02 | 112.00 |
TherapeuticsMD has lower revenue, but higher earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Liquidia has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Liquidia and TherapeuticsMD, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Liquidia | 2 | 3 | 5 | 1 | 2.45 |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
Liquidia presently has a consensus price target of $98.08, indicating a potential upside of 42.92%. Given Liquidia’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Liquidia is more favorable than TherapeuticsMD.
Summary
Liquidia beats TherapeuticsMD on 12 of the 15 factors compared between the two stocks.
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
